AU Patent

AU2025203526A1 — Liquid pharmaceutical formulations of PTH conjugates

Assigned to Ascendis Pharma Bone Diseases AS · Expires 2025-07-03 · 1y expired

What this patent protects

#$%^&*AU2025203526A120250703.pdf##### Abstract A liquid pharmaceutical formulation, wherein the pharmaceutical formulation comprises a PTH conjugate, a buffering agent, an isotonicity agent, a preservative and optionally an antioxidant and wherein the PTH conjugate comprise…

USPTO Abstract

#$%^&*AU2025203526A120250703.pdf##### Abstract A liquid pharmaceutical formulation, wherein the pharmaceutical formulation comprises a PTH conjugate, a buffering agent, an isotonicity agent, a preservative and optionally an antioxidant and wherein the PTH conjugate comprises a PTH moiety that is covalently and reversibly conjugated to a water-soluble carrier moiety. Abstract A liquid pharmaceutical formulation, wherein the pharmaceutical formulation comprises a PTH conjugate, a buffering agent, an isotonicity agent, a preservative and optionally an antioxidant and wherein the PTH conjugate comprises a PTH moiety that is covalently and reversibly conjugated to a water-soluble carrier moiety.

Drugs covered by this patent

Patent Metadata

Patent number
AU2025203526A1
Jurisdiction
AU
Classification
—
Expires
2025-07-03
Drug substance claim
No
Drug product claim
No
Assignee
Ascendis Pharma Bone Diseases AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.